APSR2026-688

 
Late-Breaking
Submitted
Poster Presentation
 
AP06-007
P07
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1215829-46904-APSR-688_440084.pdf
Format: PDF Only
01. Clinical Respiratory Medicine
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Nicole Niu * Waikato Hospital Department of Respiratory Medicine Hamilton New Zealand
Mandy Symonds - Waikato Hospital Department of Respiratory Medicine Hamilton New Zealand
Eskandarain Shafuddin - Waikato Hospital Department of Respiratory Medicine Hamilton New Zealand
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Nicole
Niu
nicole.niu53@gmail.com
+64210635916
Under 30
New Zealand
Original Research
Characteristics and care of patients with non-cystic fibrosis bronchiectasis at Waikato Hospital
Maximum 25 words
Abstract Content
Bronchiectasis is a clinically heterogeneous disease with significant morbidity and adherence to international guidelines in routine practice remains variable. This study assessed the demographics, microbiology, and care of patients with non-CF bronchiectasis at Waikato Hospital against international guidelines and EMBARC registry.
Retrospective audit of 178 patients with non-CF bronchiectasis reviewed at Respiratory outpatient clinic from January to December 2023. Data were extracted from electronic medical records.
Mean age 64 years, female 59%, Māori 29% and NZ European 59%. 50% resided rurally, and 38% had BMI ≥30. Mean FEV1% predicted was 68.2%. 39 patients (22%) had at least 1 hospitalised exacerbation in the prior year. Comorbidities and aetiology included asthma (37%), COPD (33%), gastro-oesophageal reflux disease (29%), chronic rhinosinusitis (27%), allergic bronchopulmonary aspergillosis (7%), and immunodeficiency (7%). 40% had eosinophilia (≥0.5x109/L), 29% had raised total IgE (≥100IU/ml), 11% had hypogammaglobulinaemia (IgG ≤7g/L), and 7% had elevated aspergillus precipitins (≥70mg/L). 65% had bacterial colonisation on sputum and bronchial washing cultures with Haemophilus influenzae (31%), Pseudomonas aeruginosa (20%), Staphylococcus aureus (4%), Moraxella catarrhalis (4%), and Streptococcus pneumoniae (3%). 18% had non-tuberculous mycobacteria (NTM) and prevalence was higher in urban (21%) than rural (15%) and higher in NZ European (20%) than Māori (12%) patients. Guideline adherence was variable. Airway clearance education was provided in 64%, self-management plan in 71%, and antibiotic advice in 54%. 19% received macrolide prophylaxis. 10% attended pulmonary rehabilitation. Only 1 patient received long-term inhaled antibiotics. 76% received inhaled corticosteroids (ICS) with 20% without documented asthma or COPD.
Although overall care meets international standards, there are notable gaps that need addressing to better align with BTS, TSANZ, and ERS guidelines. Bacterial colonisation was similar to the EMBARC registry, but NTM detection was higher, indicating a need to examine local environmental and diagnostic factors.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Bronchiectasis, New Zealand
maximum 3 keywords and no abbreviations, separated by commas
 
300